In late July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides, including BPC-157 and TB-500, for inclusion on the agency's list of substances pharmacies may legally compound. The vote directly contradicts the unanimous position of the FDA's own career scientists, and it partially reverses a crackdown this site covered when the agency first moved against these compounds.
What the Committee Actually Voted On
At a meeting held July 23-24, 2026, the PCAC reviewed a slate of peptides for possible addition to the 503A Bulk Drug Substances List, the list that determines which unapproved substances compounding pharmacies may legally prepare into individualized prescriptions. The panel voted to recommend six: BPC-157, TB-500, KPV, MOTS-C, Semax, and Epitalon.
The review followed a February 27, 2026 announcement from the Department of Health and Human Services reclassifying roughly a dozen research peptides, moving several from a more restricted category toward one that made this kind of compounding review possible in the first place.
Why This Is Notable
This site previously covered the FDA's determination that BPC-157 and TB-500 lacked adequate safety data to qualify for the bulk substances list, a decision that pushed both compounds further into the unregulated "research use only" market. The July vote suggests the regulatory picture is shifting again, but it is worth being precise about what changed and what didn't.
According to reporting on the meeting, FDA scientific staff who reviewed the human clinical data on these compounds found what one summary described as "effectively an absence of human clinical data" supporting their safety and effectiveness for any indication. The committee's recommendation to move forward anyway, over that internal scientific objection, is the unusual part of this story.
What a Committee Vote Does Not Mean
An advisory committee recommendation is not a rule change, and nothing about pharmacy compounding of these peptides became legal on the day of the vote. The FDA must still decide whether to accept the panel's recommendation, and any actual addition to the bulk substances list would go through formal notice-and-comment rulemaking, a process that typically takes many months and sometimes longer than a year. Compounding pharmacies cannot legally prepare BPC-157 or TB-500 today on the strength of this vote alone.
What Hasn't Changed
Separately from the compounding question, none of these six peptides has been evaluated or approved by the FDA as a safe and effective drug for any human use. The clinical evidence for BPC-157 and TB-500 specifically remains overwhelmingly limited to animal and cell-culture research, a point covered in more depth in this site's dedicated guides to each compound. A favorable compounding recommendation would, if finalized, change who is legally allowed to prepare these substances and under what oversight; it would not itself supply the missing human trial data or establish a dosing standard.
What to Watch Next
The practical next steps are the FDA's formal response to the committee's recommendation and, if the agency moves forward, a public rulemaking process that includes an opportunity for comment. Until any new rule is finalized, the products sold today as BPC-157 or TB-500 continue to come almost entirely from an unregulated supply chain outside the compounding system this vote concerns, with no standardized dosing or verified purity. Anyone currently using or considering these compounds should discuss that unregulated status with a licensed physician rather than treating this vote as a signal that anything has already become an approved or standardized therapy.